Brought to you by 
Shire gets access to Sangamo's ZFP technology
20 Jun 2016
Executive Summary
Sangamo BioSciences Inc. (developing DNA-binding proteins for gene regulation and genome editing) has licensed Shire PLC exclusive worldwide rights to develop therapeutics that incorporate Sangamo’s ZFP (zinc finger DNA-binding protein) technology for hemophilia A and B and other genetic diseases such as lysosomal storage disorders.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
-
Drug Discovery Tools
- Genomics-Proteomics
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Shire gets access to Sangamo's ZFP technology
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice